AIDS vaccine: Signs of progress after three years of disappointment

Nov 11, 2010 By Alvin Powell
“It is a really exciting time in AIDS vaccines," Seth Berkley, president and CEO of the International AIDS Vaccine Initiative, told his Harvard School of Public Health audience. "We are in an AIDS vaccine renaissance. The science is moving on as we are talking.” Photo credit: Justin Ide/Harvard Staff Photographer

Just three years after the high-profile failure of an AIDS vaccine trial sent researchers back to the drawing board, optimism is again rising about the prospects of protecting humanity from a disease that ranks among the deadliest in history.

Seth Berkley, president and chief executive officer of the International AIDS Vaccine Initiative (IAVI), outlined new approaches, new discoveries, and one moderately successful recent vaccine trial that he said paves the way for real progress toward ending a pandemic that in 2008 alone infected an estimated 2.7 million and killed 2 million.

Though the spread of antiretroviral treatment to the has improved the prognosis of those getting the drugs, the drugs are still unavailable to many, which means that /AIDS remains a killer for most sufferers, Berkley said.

Berkley spoke Tuesday (Nov. 9) at the Harvard School of Public Health (HSPH), where he delivered a Dean’s Distinguished Lecture on the subject. HSPH Dean Julio Frenk introduced Berkley, calling the AIDS “the single most important public health crisis in the history of humankind.”

In 2007, the failure of a by pharmaceutical giant Merck sent a wave of pessimism crashing over the community. Considered at the time the most advanced candidate for a successful vaccine, its failure — and the evidence that it might have actually increased the risk of contracting HIV — left researchers feeling as if they had to start from scratch.

In the years since, however, several breakthroughs have advanced vaccine efforts, Berkley said. One is the discovery of 15 antibodies in humans that provide new avenues through which to attack the virus. A second is the promise shown by new viral vectors — used to deliver a vaccine to the target — and the third is a 2009 trial in Thailand of a vaccine that appears to have provided protection against HIV for about 30 percent of those inoculated. While Berkley said the Thai trial provided just “modest” protection, it has raised hope that a more potent vaccine can be developed.

“It is a really exciting time in AIDS vaccines. We are in an vaccine renaissance,” Berkley said. “The science is moving on as we are talking.”

Despite his optimism, Berkley said that creating a vaccine against HIV remains a major scientific challenge. The primary reason HIV is so difficult to protect against is that the virus mutates very rapidly, so a vaccine that protects against one strain or substrain may provide little or no protection against another.

The discovery of the new antibodies, some of which are particularly potent against HIV, offers both new candidates for a vaccine and new strategies short of development of a full vaccine. The antibodies themselves could be injected as a temporary immunization measure, much as gamma globulin was once given to protect against hepatitis A.

Work toward a vaccine involves both branches of the human immune system, Berkley said. In addition to the branch that uses antibodies to destroy invading pathogens, the second branch of the immune system, called cell-mediated immunity, sends natural killer cells, macrophages, and other immune cells to attack invaders. Berkley said several efforts are under way to mobilize cell-mediated immunity against HIV.

Researchers are also focusing on the best way to deliver a vaccine. Results on self-replicating vectors that multiply inside the body have been promising in laboratory monkeys, he said. Using the monkey analog to HIV, the simian immune virus, or SIV, research with self-replicating viral vectors has shown promising results, with 54 percent of those vaccinated able to entirely clear the virus from their bodies.

Harvard’s teaching hospitals are among those institutions involved in vaccine development efforts, with Massachusetts General Hospital and Beth Israel Deaconess Medical Center teaming up on one effort in clinical trials, together with IAVI and other collaborators.

Berkley said it’s important to think about delivering a vaccine where it’s most needed once it’s developed. Though some believe that delivery of a vaccine to the developing world would naturally be a high priority, he said recent history with the vaccine against human papillomavirus (HPV) — a leading cause of cervical cancer — shows that it will take more than assumptions to deliver vaccines where they’re needed. Though the HPV was licensed in 2006, it is still unavailable in most of the developing world, Berkley said.

Explore further: Scientists discover how a killer fungus attacks HIV patients

add to favorites email to friend print save as pdf

Related Stories

AIDS vaccine trial exceeds expectations

Sep 23, 2005

An experimental AIDS vaccine of Merck & Co. has exceeded expectations and led to a double enrollment in the trial to 3,000, researchers said.

Clinical trial will test new HIV/AIDS vaccine

Apr 03, 2008

A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Women’s Hospital (BWH). This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought ...

How HIV vaccine might have increased odds of infection

Nov 03, 2008

In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection. A new study by a team of researchers at the Montpellier ...

AIDS experts go back to basics

Mar 27, 2008

The head of the U.S. agency in charge of AIDS research says scientists need to go back to basics to find a vaccine against the HIV virus.

Recommended for you

Harm-reduction program optimizes HIV/AIDS prevention

Apr 21, 2014

(Medical Xpress)—New research from UC San Francisco and the San Francisco AIDS Foundation has found that clients participating in a harm-reduction substance use treatment program, the Stonewall Project, decrease their use ...

User comments : 0

More news stories

Sensors may keep hospitalized patients from falling

(Medical Xpress)—To keep hospitalized patients safer, University of Arizona researchers are working on new technology that involves a small, wearable sensor that measures a patient's activity, heart rate, ...

Fresh hope for preventing pneumonia in the elderly

There are calls for the frail and elderly not be be overlooked for vaccines against pneumonia this winter, with UNSW research challenging conventional wisdom on immunisation effectiveness in older patients.

Phase transiting to a new quantum universe

(Phys.org) —Recent insight and discovery of a new class of quantum transition opens the way for a whole new subfield of materials physics and quantum technologies.

Imaging turns a corner

(Phys.org) —Scientists have developed a new microscope which enables a dramatically improved view of biological cells.

NASA image: Volcanoes in Guatemala

This photo of volcanoes in Guatemala was taken from NASA's C-20A aircraft during a four-week Earth science radar imaging mission deployment over Central and South America. The conical volcano in the center ...